Related Experiment Videos
[Chemiluminescent immunoassay for anti-granulocyte antibody IgG]
Insights
A novel solid-phase competitive chemiluminescent immunoassay (CLIA) was developed for detecting anti-granulocyte antibody (AGAb) IgG. This assay shows potential for diagnosing AGAb in leukocytopenic individuals.
Area of Science:
- Immunology
- Analytical Chemistry
- Biochemistry
Context:
- Anti-granulocyte antibodies (AGAb) are implicated in various hematological disorders.
- Accurate detection of AGAb is crucial for diagnosis and management.
- Existing immunoassay methods may have limitations in sensitivity or specificity.
Purpose:
- To develop and validate a solid-phase competitive chemiluminescent immunoassay (CLIA) for quantifying anti-granulocyte antibody (AGAb) IgG.
- To evaluate the diagnostic performance of the CLIA method in distinguishing between patient groups.
Summary:
- A competitive chemiluminescent immunoassay (CLIA) was established using N-(4-amiobytul)-N-ethylisoluminol (ABEI)-labeled antibodies and an ABEI-CoCl2-H2O2 chemiluminescent system.
- The assay demonstrated a low limit of detection (3.0 x 10(-14) mol ABEI/tube).
- In a study of 131 individuals, the CLIA, using the chemiluminescent index (CLI), identified a significantly higher positive rate of AGAb in the leukocytopenic group compared to the control group (P < 0.005).
Impact:
- The developed CLIA method offers a sensitive and specific tool for AGAb detection.
- The assay showed promising diagnostic capabilities with a specificity of 90.2% and accuracy of 62.6%.
- This assay could aid in the diagnosis and understanding of conditions associated with AGAb.
Abstract:
In this paper is reported solid phase competitive chemiluminescent immunoassay (CLIA) for anti-granulocyte antibody (AGAb) IgG with N-(4-amiobytul)-N-ethylisoluminol (ABEI) labelled rabbit antibody IgG against granulocyte competing with the analyte and ABEI-CoCl2-H2O2 as the chemiluminescent system. The absolute limit of detection was 3.0 x 10(-14) mol ABEI/tube. One hundred and thirty one individuals were divided into three groups: leukocytopenic group (n = 58), control group (n = 41) and normal group (n = 32). Chemiluminescent index (CLI) was used as the diagnostic criterion for AGAb in serum. The results showed that the positive rate of the leukocytopenic group was significantly higher than that of the control group (P < 0.005), and the sensitivity, specificity and accuracy of the method were 43.1%, 90.2% and 62.6%, respectively.